Biogen’s aducanumab in AD unlikely to be well-covered by payers, with FDA approval prospects mixed - GlobalData
Newton states: “High coinsurance requirements and stringent prior authorization, including expensive testing to determine eligibility, could mean far less than 10% of eligible patients take aducanumab if it gains FDA approval.”
Newton states: “High coinsurance requirements and stringent prior authorization, including expensive testing to determine eligibility, could mean far less than 10% of eligible patients take aducanumab if it gains FDA approval.”